Encompass Health (EHC)
(Delayed Data from NYSE)
$103.53 USD
+1.62 (1.59%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $103.58 +0.05 (0.05%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$103.53 USD
+1.62 (1.59%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $103.58 +0.05 (0.05%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth A Momentum A VGM
Zacks News
Encompass Health (EHC) Stock Down Despite Q1 Earnings Beat
by Zacks Equity Research
Encompass Health (EHC) increases its guidance for net operating revenues, which is in the range of $5.25-$5.325 million for 2024.
Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Amedisys (AMED) tops on revenue and earnings estimates in the first quarter of fiscal 2024.
Why Encompass Health (EHC) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Encompass Health Corporation (EHC) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Encompass Health (EHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Encompass Health (EHC) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's What Key Metrics Tell Us About Encompass Health (EHC) Q1 Earnings
by Zacks Equity Research
The headline numbers for Encompass Health (EHC) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Watch These 5 Medical Stocks for Q1 Earnings: Beat or Miss?
by Debasmita Chatterjee
Improved premiums resulting from membership growth, and higher patient admissions are expected to have driven the Q1 performance of HUM, MOH, UHS, EHC and CYH. An elevated operating expense level is likely to have dented growth prospects.
Insights Into Encompass Health (EHC) Q1: Wall Street Projections for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Encompass Health (EHC) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Should You Buy Encompass Health (EHC) Ahead of Q1 Earnings?
by Zacks Equity Research
Encompass Health's (EHC) Q1 results are likely to benefit on the back of growing patient volumes and commendable expansion initiatives.
Elevance Health (ELV), CD&R to Unveil Primary Care Offering
by Zacks Equity Research
Elevance Health (ELV) forms an alliance with CD&R to enhance primary care delivery by making collective use of the partners' assets and subsequently, reduce overall costs of care.
Are Investors Undervaluing Encompass Health (EHC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should Value Investors Buy DaVita (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Encompass Health (EHC) Plans a 50-Bed Facility to Serve Texas
by Zacks Equity Research
Encompass Health (EHC) unveils plans to build an inpatient rehabilitation hospital in San Antonio to bring improved health outcomes and further fortify its presence in Texas.
Here's Why Encompass Health (EHC) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Encompass Health (EHC) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Is Amedisys (AMED) Down 2.5% Since Last Earnings Report?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Encompass Health (EHC) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Encompass Health (EHC) Up 42% in a Year: What Lies Ahead?
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth on the back of sustained top-line growth, an expanding healthcare facility portfolio and robust cash-generating abilities.
An In-Depth Analysis of Encompass Health's (EHC) 2024 Outlook
by Zacks Equity Research
Growth in Medicare and Managed Care pricing, along with capacity additions of six de novos with 280 beds, will likely have an impact on Encompass Health's (EHC) 2024 bottom line.
Encompass Health (EHC), Piedmont to Build Loganville Facility
by Zacks Equity Research
Encompass Health (EHC) partners with Piedmont to construct a 40-bed inpatient rehabilitation hospital in Georgia to better serve the rehabilitative care needs of the state and solidify its footprint.
Here's Why Encompass Health (EHC) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Is Encompass Health (EHC) Up 5.3% Since Last Earnings Report?
by Zacks Equity Research
Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.